Lexicon Pharmaceuticals (LXRX) Short Interest Ratio & Short Volume → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free LXRX Stock Alerts $1.77 0.00 (0.00%) (As of 05:07 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Lexicon Pharmaceuticals Short Interest DataCurrent Short Interest23,440,000 sharesPrevious Short Interest20,120,000 sharesChange Vs. Previous Month+16.50%Dollar Volume Sold Short$36.10 millionShort Interest Ratio5.3 Days to CoverLast Record DateApril 30, 2024Outstanding Shares246,240,000 sharesPercentage of Shares Shorted9.52%Today's Trading Volume2,567,096 sharesAverage Trading Volume4,082,476 sharesToday's Volume Vs. Average63% Short Selling Lexicon Pharmaceuticals ? Sign up to receive the latest short interest report for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLXRX Short Interest Over TimeLXRX Days to Cover Over TimeLXRX Percentage of Float Shorted Over Time Ad Stansberry ResearchWhat President Biden's new law means for investorsWhat's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it.This expert just went public with all the details, including which stocks to jump on immediately. Lexicon Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202423,440,000 shares $36.10 million +16.5%N/A5.3 $1.54 4/15/202420,120,000 shares $37.62 million -8.2%N/A4.2 $1.87 3/31/202421,910,000 shares $52.58 million +2.6%N/A4.7 $2.40 3/15/202421,350,000 shares $55.51 million +1.3%N/A4.6 $2.60 2/29/202421,070,000 shares $52.46 million -10.0%N/A4.9 $2.49 2/15/202423,410,000 shares $83.81 million +1.7%N/A6.4 $3.58 Get the Latest News and Ratings for LXRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/202423,030,000 shares $43.07 million -8.9%N/A8 $1.87 1/15/202425,270,000 shares $34.62 million +8.8%N/A10.3 $1.37 12/31/202323,220,000 shares $35.53 million -0.3%N/A8.6 $1.53 12/15/202323,280,000 shares $29.57 million -0.5%N/A9.1 $1.27 11/30/202323,400,000 shares $24.80 million +4.6%N/A9.3 $1.06 11/15/202322,370,000 shares $25.50 million +1.8%N/A9.3 $1.14 10/31/202321,980,000 shares $27.26 million +12.7%N/A9.9 $1.24 10/15/202319,500,000 shares $23.21 million -3.7%N/A9.1 $1.19 9/30/202320,240,000 shares $22.06 million +7.1%N/A11.2 $1.09 9/15/202318,900,000 shares $26.46 million +6.1%N/A11.5 $1.40 8/31/202317,810,000 shares $30.63 million +1.5%N/A9.5 $1.72 8/15/202317,550,000 shares $28.61 million -2.2%N/A6.6 $1.63 7/31/202317,950,000 shares $36.08 million +14.2%N/A6.9 $2.01 7/15/202315,720,000 shares $34.74 million +8.7%N/A6.3 $2.21 6/30/202314,460,000 shares $33.11 million +38.0%N/A6.1 $2.29 6/15/202310,480,000 shares $26.93 million -2.6%N/A4.9 $2.57 5/31/202310,760,000 shares $35.51 million +66.8%N/A6.3 $3.30 5/15/20236,450,000 shares $19.22 million +30.8%N/A8.5 $2.98 4/30/20234,930,000 shares $11.78 million +17.4%N/A8.1 $2.39 4/15/20234,200,000 shares $10.12 million +3.5%N/A9.5 $2.41 3/31/20234,060,000 shares $9.87 million +2.3%N/A10.3 $2.43 3/15/20233,970,000 shares $9.09 million +4.2%N/A9.3 $2.29 2/28/20233,810,000 shares $8.57 million -8.0%N/A9.3 $2.25 2/15/20234,140,000 shares $9.44 million +3.5%N/A11.3 $2.28 1/31/20234,000,000 shares $8.96 million +2.6%N/A10.6 $2.24 1/15/20233,900,000 shares $9.20 million +0.3%N/A9.8 $2.36 12/30/20223,890,000 shares $7.43 million +2.9%N/A9.3 $1.91 12/15/20223,780,000 shares $8.05 million +0.3%N/A8.6 $2.13 11/30/20223,770,000 shares $8.07 million -2.3%N/A7.8 $2.14 11/15/20223,860,000 shares $8.96 million -9.4%N/A7.5 $2.32 10/31/20224,260,000 shares $9.16 million -4.7%N/A6.4 $2.15 10/15/20224,470,000 shares $9.43 million -0.2%N/A4.4 $2.11 9/30/20224,480,000 shares $10.75 million +11.4%N/A4.3 $2.40 9/15/20224,020,000 shares $10.77 million +7.8%N/A2.4 $2.68Boost your retirement with these AI payouts (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. 8/31/20223,730,000 shares $10.26 million +1.9%N/A2.2 $2.75 8/15/20223,660,000 shares $12.55 million -55.2%N/A2.2 $3.43 7/31/20228,170,000 shares $19.44 million -0.9%N/A5.3 $2.38 7/15/20228,240,000 shares $25.38 million +6.6%8.0%6.9 $3.08 6/30/20227,730,000 shares $14.38 million +34.4%7.5%6.6 $1.86 6/15/20225,750,000 shares $8.05 million +5.7%5.6%10.5 $1.40 5/31/20225,440,000 shares $9.63 million +1.3%N/A10.9 $1.77 5/15/20225,370,000 shares $9.29 million +0.9%N/A8.8 $1.73 4/30/20225,320,000 shares $9.63 million +11.5%N/A8.4 $1.81 4/15/20224,770,000 shares $11.11 million +2.8%N/A7.3 $2.33 3/31/20224,640,000 shares $9.70 million -2.1%N/A7.1 $2.09 3/15/20224,740,000 shares $9.24 million -2.1%N/A6.8 $1.95 2/28/20224,840,000 shares $10.02 million +8.3%N/A6.8 $2.07 2/15/20224,470,000 shares $13.50 million +17.6%N/A7 $3.02 1/31/20223,800,000 shares $12.05 million +5.3%N/A5.9 $3.17 1/15/20223,610,000 shares $12.45 million +1.4%N/A5.6 $3.45 12/31/20213,560,000 shares $14.03 million +10.9%N/A5 $3.94 12/15/20213,210,000 shares $12.78 million -10.6%N/A4.3 $3.98 11/30/20213,590,000 shares $16.44 million -0.6%N/A4.9 $4.58 11/15/20213,610,000 shares $18.59 million +8.4%N/A4.1 $5.15 10/29/20213,330,000 shares $17.62 million -2.4%2.4%3.5 $5.29 10/15/20213,410,000 shares $21.01 million -2.9%2.4%3.6 $6.16 9/30/20213,510,000 shares $16.88 million -4.6%2.5%3.8 $4.81 9/15/20213,680,000 shares $16.71 million -11.1%2.6%3.4 $4.54 8/31/20214,140,000 shares $19.54 million +16.6%3.0%4 $4.72 8/13/20213,550,000 shares $12.89 million -8.5%2.5%4 $3.63 7/30/20213,880,000 shares $13.74 million -3.2%2.8%4.7 $3.54 7/15/20214,010,000 shares $14.80 million -8.2%2.9%4.9 $3.69 6/30/20214,370,000 shares $20.06 million +24.2%3.1%5.2 $4.59 6/15/20213,520,000 shares $16.68 million -3.3%2.5%5.3 $4.74 5/28/20213,640,000 shares $15.98 million -9.0%2.6%4.7 $4.39 5/14/20214,000,000 shares $16.80 million -5.7%N/A4.5 $4.20 4/30/20214,240,000 shares $21.37 million -5.4%N/A3.9 $5.04 4/15/20214,480,000 shares $23.25 million +20.1%N/A2.9 $5.19 3/31/20213,730,000 shares $21.15 million -24.0%N/A0.8 $5.67 3/15/20214,910,000 shares $33.73 million +36.8%N/A0.9 $6.87 2/26/20213,590,000 shares $26.85 million -20.0%N/A0.4 $7.48 2/12/20214,490,000 shares $35.96 million -16.2%N/A0.5 $8.01 1/29/20215,360,000 shares $43.20 million -52.9%N/A0.5 $8.06 1/15/202111,380,000 shares $91.61 million -5.1%N/A1 $8.05 12/31/202011,990,000 shares $39.69 million -2.0%N/A1.6 $3.31 12/15/202012,240,000 shares $36.48 million +29.0%N/A1.7 $2.98 11/30/20209,490,000 shares $15.37 million -1.7%N/A1.6 $1.62 11/15/20209,650,000 shares $12.26 million -0.4%N/A3.7 $1.27 10/30/20209,690,000 shares $11.24 million +3.1%N/A11.7 $1.16 10/15/20209,400,000 shares $13.63 million -7.2%9.1%7.7 $1.45 9/30/202010,130,000 shares $14.59 million -14.4%9.8%5.9 $1.44 9/15/202011,830,000 shares $18.81 million -13.0%11.5%7.1 $1.59 8/31/202013,590,000 shares $23.78 million -9.4%13.2%7.9 $1.75 8/14/202015,000,000 shares $27.15 million -8.9%14.5%8.6 $1.81Boost your retirement with these AI payouts (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. 7/31/202016,460,000 shares $31.93 million +44.8%15.9%9.5 $1.94 7/15/202011,370,000 shares $22.29 million +9.3%11.0%8.2 $1.96 6/30/202010,400,000 shares $20.59 million -4.8%10.1%11.3 $1.98 6/15/202010,920,000 shares $20.64 million +8.6%10.6%11.7 $1.89 5/29/202010,060,000 shares $19.21 million -3.5%9.8%10.4 $1.91 5/15/202010,420,000 shares $19.59 million -0.7%10.1%10.8 $1.88 4/30/202010,490,000 shares $19.83 million -0.3%10.2%10.8 $1.89 4/15/202010,520,000 shares $21.25 million -5.9%10.2%11.1 $2.02 3/31/202011,180,000 shares $22.92 million -25.4%10.8%11.6 $2.05 3/13/202014,991,800 shares $28.18 million -9.5%14.6%14.5 $1.88 2/28/202016,570,000 shares $33.80 million +2.7%16.2%14.3 $2.04 2/14/202016,130,000 shares $37.10 million +3.2%15.7%12.7 $2.30 1/31/202015,630,000 shares $44.70 million +7.6%15.2%11.7 $2.86 1/15/202014,520,000 shares $46.75 million +6.9%14.1%10.5 $3.22 12/31/201913,580,000 shares $45.63 million +17.8%13.2%9.9 $3.36 8/15/20197,668,900 shares $10.20 million -17.4%7.5%7.1 $1.33 LXRX Short Interest - Frequently Asked Questions What is Lexicon Pharmaceuticals' current short interest? Short interest is the volume of Lexicon Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 23,440,000 shares of LXRX short. Learn More on Lexicon Pharmaceuticals' current short interest. What is a good short interest ratio for Lexicon Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LXRX shares currently have a short interest ratio of 5.0. Learn More on Lexicon Pharmaceuticals's short interest ratio. Is Lexicon Pharmaceuticals' short interest increasing or decreasing? Lexicon Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 23,440,000 shares, an increase of 16.5% from the previous total of 20,120,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Lexicon Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Lexicon Pharmaceuticals: Verastem, Inc. (3.49%), Vanda Pharmaceuticals Inc. (4.17%), XOMA Co. (2.33%), Emergent BioSolutions Inc. (14.13%), Merrimack Pharmaceuticals, Inc. (5.70%), Rigel Pharmaceuticals, Inc. (3.23%), Regulus Therapeutics Inc. (7.33%), Rezolute, Inc. (0.78%), OPKO Health, Inc. (26.42%), Innoviva, Inc. (18.39%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Lexicon Pharmaceuticals stock? Short selling LXRX is an investing strategy that aims to generate trading profit from Lexicon Pharmaceuticals as its price is falling. LXRX shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Lexicon Pharmaceuticals? A short squeeze for Lexicon Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LXRX, which in turn drives the price of the stock up even further. How often is Lexicon Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LXRX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: VSTM Short Interest Data VNDA Short Interest Data XOMA Short Interest Data EBS Short Interest Data MACK Short Interest Data RIGL Short Interest Data RGLS Short Interest Data RZLT Short Interest Data OPK Short Interest Data INVA Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LXRX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 Media"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Former CIA advisor: Dark side of AI now startingParadigm Press